Profile data is unavailable for this security.
About the company
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
- Revenue in DKK (TTM)1.90bn
- Net income in DKK-464.78m
- Incorporated1992
- Employees759.00
- LocationBavarian Nordic A/SPhilip Heymans Alle 3HELLERUP 2900DenmarkDNK
- Websitehttps://www.bavarian-nordic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical Science Sweden AB | 347.29m | 71.92m | 5.28bn | 224.00 | 58.85 | 2.07 | 53.66 | 15.56 | 2.54 | 2.54 | 11.73 | 72.32 | 0.1935 | 2.22 | 6.80 | 2,338,335.00 | 4.01 | 3.41 | 4.27 | 3.67 | 69.07 | 78.80 | 20.71 | 15.42 | 2.18 | -- | 0.0432 | 0.00 | 249.98 | 47.90 | 452.66 | 92.43 | 4.25 | -- |
| Zealand Pharma A/S | 259.83m | -957.00m | 5.70bn | 345.00 | -- | 7.46 | -- | 21.94 | -22.16 | -23.12 | 6.02 | 16.42 | 0.1297 | 1.99 | 3.89 | 731,901.40 | -47.76 | -31.81 | -57.58 | -37.07 | 62.29 | -- | -368.33 | -247.19 | 4.78 | -- | 0.5268 | -- | -17.19 | 4.85 | -20.24 | -- | 53.47 | -- |
| BioGaia AB | 676.48m | 174.79m | 6.30bn | 195.00 | 37.90 | 5.34 | 33.33 | 9.44 | 2.44 | 2.44 | 9.43 | 17.30 | 0.4738 | -- | -- | 5,700,270.00 | 12.24 | 18.70 | 13.32 | 21.27 | 73.01 | 74.18 | 25.84 | 26.20 | -- | 351.31 | 0.00 | 75.30 | 5.09 | 7.99 | 9.20 | 4.22 | 38.51 | -0.6484 |
| Nykode Therapeutics ASA | 250.42m | -71.73m | 7.84bn | 128.00 | -- | 5.79 | -- | 31.94 | -0.3771 | -0.3771 | 1.16 | 6.28 | 0.1433 | -- | 3.82 | 3,240,462.00 | -4.10 | 25.30 | -4.53 | 27.55 | -- | -- | -28.64 | 46.19 | -- | -- | 0.0357 | -- | -84.20 | 311.05 | -106.29 | -- | 157.24 | -- |
| Swedencare AB (publ) | 945.38m | 69.82m | 8.52bn | 513.00 | 123.90 | 1.65 | 41.16 | 9.05 | 0.6147 | 0.6147 | 9.68 | 46.12 | 0.2073 | 2.30 | 8.51 | 4,751,254.00 | 1.53 | 4.78 | 1.60 | 5.07 | 51.67 | 57.82 | 7.39 | 11.94 | 1.18 | -757.78 | 0.1812 | 32.49 | 221.77 | 70.46 | 63.76 | 41.06 | -- | -- |
| Camurus AB | 556.95m | -9.02m | 9.01bn | 157.00 | -- | 14.46 | 58,842.29 | 16.37 | -0.2385 | -0.2385 | 14.19 | 16.13 | 0.7195 | 0.8986 | 6.19 | 5,295,548.00 | -1.17 | -27.66 | -1.46 | -33.82 | 87.20 | 86.73 | -1.62 | -84.90 | 2.77 | -10.60 | 0.0245 | -- | 78.74 | 39.49 | 45.93 | -- | 1.59 | -- |
| Karo Pharma AB | 2.46bn | -134.84m | 9.92bn | 242.00 | -- | 1.70 | 59.49 | 4.04 | -0.7652 | -0.7652 | 14.59 | 30.22 | 0.2187 | 2.69 | 5.34 | 14,351,360.00 | -1.20 | 1.79 | -1.50 | 2.49 | 56.67 | 55.56 | -5.47 | 7.45 | 1.82 | 0.2112 | 0.5139 | 3.50 | 2.72 | 53.52 | -121.27 | -- | -4.89 | -- |
| AddLife AB | 6.14bn | 436.75m | 13.28bn | 2.19k | 33.01 | 4.44 | 15.75 | 2.26 | 5.02 | 5.02 | 70.57 | 37.30 | 0.7548 | 3.93 | 6.14 | 4,793,896.00 | 5.40 | 9.03 | 10.88 | 17.10 | 37.64 | 35.74 | 7.15 | 7.57 | 0.2799 | 6.78 | 0.557 | 34.17 | 51.57 | -- | 38.78 | -- | -- | -- |
| Bavarian Nordic A/S | 1.90bn | -464.78m | 23.36bn | 759.00 | -- | 3.19 | -- | 12.41 | -7.48 | -7.48 | 30.41 | 104.70 | 0.1821 | 2.65 | 7.09 | 2,500,494.00 | -4.46 | -2.42 | -5.17 | -2.93 | 30.05 | 45.79 | -24.49 | -11.37 | 2.24 | -7.69 | 0.3584 | -- | 2.46 | 13.52 | -267.47 | -- | 49.64 | -- |
| ALK-Abello A/S | 4.05bn | 255.00m | 28.12bn | 2.57k | 121.74 | 8.52 | 55.98 | 7.08 | 1.16 | 1.16 | 18.45 | 16.60 | 0.6892 | 1.34 | 5.89 | 1,596,374.00 | 4.34 | -0.5115 | 5.47 | -0.6163 | 61.85 | 58.11 | 6.30 | -0.8118 | 0.9756 | 20.06 | 0.146 | -- | 12.17 | 5.44 | 776.00 | -4.10 | 3.17 | -- |
| Vitrolife AB | 1.78bn | 247.98m | 28.39bn | 1.16k | 111.85 | 2.58 | 67.69 | 16.47 | 2.72 | 2.72 | 19.53 | 118.01 | 0.2231 | 3.60 | 7.42 | 5,856,668.00 | 3.12 | 8.88 | 3.27 | 9.55 | 58.02 | 63.53 | 14.00 | 24.08 | 1.30 | 20.95 | 0.1278 | 23.22 | 34.94 | 14.45 | 18.87 | 12.36 | 35.34 | 9.00 |
| H. Lundbeck A/S | 16.40bn | 1.11bn | 34.22bn | 5.35k | 6.31 | 0.3792 | 12.61 | 2.13 | 5.58 | 5.58 | 82.56 | 92.86 | 0.4716 | 1.16 | 4.22 | 3,066,193.00 | 3.19 | 8.13 | 4.13 | 11.54 | 78.37 | 78.05 | 6.76 | 13.60 | 0.7058 | 2.90 | 0.2597 | 48.48 | -7.77 | 0.8366 | -16.64 | 1.71 | 12.34 | -3.98 |
Data as of Aug 15 2022. Currency figures normalised to Bavarian Nordic A/S's reporting currency: Danish Krone DKK
16.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Advisers, Inc.as of 30 Jun 2022 | 2.93m | 4.16% |
| The Vanguard Group, Inc.as of 05 Aug 2022 | 1.90m | 2.70% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 1.72m | 2.44% |
| Dimensional Fund Advisors LPas of 04 Aug 2022 | 1.11m | 1.57% |
| Polar Capital LLPas of 29 Apr 2022 | 1.00m | 1.42% |
| BlackRock Fund Advisorsas of 03 Aug 2022 | 905.07k | 1.28% |
| Nykredit Bank A/S (Investment Management)as of 30 Jun 2022 | 687.66k | 0.98% |
| Allianz Global Investors GmbHas of 30 Apr 2022 | 614.32k | 0.87% |
| Max Mitteregger Kapitalf�rvaltning ABas of 31 Dec 2016 | 442.44k | 0.63% |
| Handelsbanken Fonder ABas of 31 Jul 2022 | 434.59k | 0.62% |
More ▼
Data from 31 Dec 2016 - 30 Jun 2022Source: FactSet Research Systems Inc.
